𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adjuvant, specific, active immunotherapy for resectable squamous cell lung carcinoma: A 5-year survival analysis

✍ Scribed by Hiroshi Takita; Ariel C. Hollinshead; Richard H. Adler; Joginder Bhayana; Michael Ramundo; Robert Moskowitz; UMA N. M. Rao; Sankaranarayanan Raman

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
446 KB
Volume
46
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Comparison of Survival and Disease-Spe
A Comparison of Survival and Disease-Specific Survival in Surgically Resected, Lymph Node-Positive Bronchioloalveolar Carcinoma Versus Nonsmall Cell Lung Cancer: Implications for Adjuvant Therapy
✍ David H. Garfield; Wilbur A. Franklin πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 62 KB πŸ‘ 1 views

T he recent article by Varlotto et al 1 raises issues that are prob- lematic in the recent and current bronchioloalveolar (BAC) literature. The third edition of the 1999 World Health Organization (WHO) consensus classification redefined BAC as an in situ tumor with a pure BAC growth pattern and with

A comparison of survival and disease-spe
A comparison of survival and disease-specific survival in surgically resected, lymph node-positive bronchioloalveolar carcinoma versus nonsmall cell lung cancer : Implications for adjuvant therapy
✍ John M. Varlotto; John C. Flickinger; Abram Recht; Margaret C. Nikolov; Malcolm πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 151 KB πŸ‘ 1 views

## Abstract ## BACKGROUND The objective of this study was to assess whether disease‐specific survival (DSS) and overall survival (OS) differed among patients who had N1 and N2 bronchioloalveolar carcinoma (BAC) compared with patients who had non‐BAC nonsmall cell lung cancer (NSCLC). ## METHODS